Vivani Medical Unveils Exciting Future with Cortigent Spin-off

Vivani Medical's Bold Move Towards Innovation

Cortigent is making waves in the field of brain implant technologies, establishing itself as a pioneer in precision neurostimulation. Notably, it stands as the sole developer with FDA approval for a device that delivers artificial vision to profoundly blind individuals.

A Mission to Transform Lives

The Cortigent Orion artificial vision system represents a groundbreaking advancement aimed at treating blindness resulting from common medical conditions. After a successful six-year Early Feasibility Study, this innovative device showcases promising capabilities in restoring vision.

The Spin-off: A Strategic Opportunity

Vivani Medical, Inc. (NASDAQ: VANI), a clinical-stage biopharmaceutical company known for its pioneering drug delivery systems, has announced that it is moving forward with a planned spin-off of Cortigent, its specialized subsidiary. This decision is set to amplify both companies' focus on their unique areas of innovation.

Shareholders of Vivani who are on record by October 8, 2025, will be entitled to shares in Cortigent. The company is gearing up to be listed on the Nasdaq under the ticker symbol “CRGT”, pending regulatory approvals. The specific distribution timeline and share allocation will be disclosed later.

Shared Vision and Growth Potential

As Vivani's CEO Adam Mendelsohn noted, this spin-off is a strategic move aimed at creating two companies that are more agile and focused in their domains. By establishing Cortigent as an independently traded company, Vivani shareholders will have a direct stake in Cortigent's advancements in the field of neurostimulation technology.

Cortigent's Future Path

Cortigent's CEO, Jonathan Adams, emphasizes the spin-off's potential to streamline operations and dedicate resources towards innovative research. This new chapter aims to position Cortigent at the forefront of the neuromodulation arena, a field that utilizes the latest advances in artificial intelligence to fulfill significant medical needs.

The immediate next steps after the spin-off include initiating the planned pivotal clinical trial for the Orion system, which aims to secure FDA approval. Additionally, Cortigent will commence its Early Feasibility Study focused on its Stroke Recovery System, enhancing its commitment to addressing critical health challenges.

Enhancing Operational Flexibility

The anticipated benefits of Cortigent's spin-off are considerable. Both companies will have the flexibility to execute their business strategies without the constraints typically associated with shared operations. This approach will allow for better capital structuring and drive growth opportunities through acquisitions and partnerships.

Investing in Neuromodulation Technology

Once publicly traded, Cortigent will provide a unique investment opportunity for stakeholders interested in pioneering developments within the biotechnological framework. With a rich history of success in transforming patient healthcare outcomes, the company aims to build upon its technological successes and continue its impactful narrative.

Adams, who has been steering Cortigent since March 2023, will maintain his leadership role post-spin-off as they remain headquartered in the Los Angeles area. Vivani will support Cortigent during this transition phase to ensure a smooth operational handover.

Timeline and Regulatory Framework

Plans for the spin-off are slated for completion in late 2025, contingent upon fulfilling several regulatory conditions. These involve procuring a favorable tax opinion and finalizing a registration statement with the U.S. Securities and Exchange Commission.

This spin-off represents a significant milestone in the evolution of both Vivani Medical and Cortigent, enhancing shareholder value and fostering a new wave of medical innovation.

Frequently Asked Questions

What is the focus of the spin-off company, Cortigent?

Cortigent focuses on developing advanced brain implant devices utilizing neurostimulation technology to help patients recover critical body functions.

When is the expected completion date for the Cortigent spin-off?

The spin-off is anticipated to be finalized by late 2025, depending on several regulatory conditions.

What will Vivani's investors receive from the spin-off?

Vivani investors holding shares as of the record date will receive shares in Cortigent, facilitating direct investment in its innovations.

How will the spin-off benefit both companies?

The spin-off allows each company to focus on their respective strategies and streamlines operations for better growth prospects.

What is the mission of Vivani Medical?

Vivani Medical aims to leverage its innovative drug delivery systems to offer extended-release biopharmaceutical implants, enhancing patient adherence to medications.

About The Author

Hi there I'm 38-year-old author and financial consultant Owen Jenkins. Having worked in the financial sector for more than ten years, I am well-versed in the subtleties and complexity that mold our financial environment. Following a degree in finance, I worked in a number of financial institutions honing my abilities in market analysis, financial planning, and investment strategies.

My love is teaching others about investing and personal finance. My goal in writing many books and articles has been to demystify financial ideas and give readers the information they need to make wise financial decisions. I write with a direct, useful style that emphasizes doable suggestions for daily living.

Along with writing, I lead webinars and seminars where I impart knowledge on how to successfully negotiate the financial world. I also write for financial journals and show up as a guest expert on financial news programs a lot. Whether they are new to investing or want to improve their approach, my mission is to enable people to take charge of their financial futures.

Beyond work, I like to hike, play the guitar, and spend time with my family. I think that balance is crucial and want to encourage people to strike a balance between their financial aspirations and their hobbies. I want to help people succeed and achieve financial security through my work, so having a good influence.

Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.